VVP/Triton Fund joins seed round funding of Abreos Biosciences
Santa Clara, CA/San Diego, CA (PRWEB) May 1, 2016
Abreos Biosciences is a health care diagnostics startup founded in San Diego, Ca. The company is pioneering point-of-care tests for personalized dosing and counterfeit detection of biologic drugs. The technology has been licensed from UC San Diego. The Triton Fund has joined in a seed stage investment round that closed in April.
The inspiration for Abreos came from Bradley Messmer. Dr. Messmer is currently on the faculty of the UC San Diego Moores Cancer Center, where he still maintains a lab. He was previously an Assistant Investigator at the Feinstein Institute for Medical Research, where he also did his postdoctoral training. After making seminal contributions to understanding the immunobiology and pathophysiology of chronic lymphocytic leukemia during his postdoctoral training, Dr. Messmer’s work has become highly multidisciplinary utilizing molecular biology, immunology, genomics, and nanotechnology to confront problems in oncology and immunotherapy.
Personalized Dosing of Biologics using Veritope Technology.
Abreos Biosciences has developed a novel, proprietary reagent platform termed Veritope for Lateral Flow Assay (LFA) and ELISA applications. Veritope reagents are mimetope peptides that mimic the ligand bound by a monoclonal antibody (mAb) and can be rapidly developed and used to measure the levels of any therapeutic mAb or other biologics in fluids such as serum or blood. Performed in the doctor’s office, infusion center or bedside, these tests can measure within minutes the concentration of active biologics in patients undergoing therapy at any given time, using blood from a single finger prick.
The importance of pharmacokinetic-based personalized dosing of biologics.
- Improved clinical trial outcomes, allowing for patient stratification based on PK
- Faster regulatory approval based on improved clinical outcome
- A reduction in risk and an increase in the potential return for any monoclonal antibody in development
New monoclonal antibodies entering the market with a companion diagnostic enabling PK measurement is likely to have a competitive advantage over other therapeutics available for similar indications. Physicians and patients will intuitively favor therapies enabling personalized dosing, as this provides invaluable reassurance that the therapeutic strategy is always tailored for maximal efficacy, for every individual. This level of confidence cannot be provided by the current dosing approach, which typically requires clinical signs of disease progression to trigger an adjustment in the therapeutic strategy or to implement a new treatment regimen. Abreos develops assays to monitor PK for any biologic drug, at any developmental stage.
About Vertical Venture Partners
Vertical Venture Partners is a venture capital firm focused on investments in companies that target specific vertical markets. Some vertical markets of interest include Retail, Healthcare, Transportation, Insurance, Financial Services and Telecommunications. Some technology areas of interest include: analytical applications, cloud applications, mobile, cyber-security, software infrastructure, materials, healthcare diagnostics and advanced instrumentation. Vertical Venture Partners will invest at any stage of a company’s growth and can help companies accelerate their usiness. For more information, interested parties may contact VVP at email@example.com.
About The Triton Fund
The Triton Fund (TTF) is a wholly owned subsidiary of Vertical Venture Partners (VVP). TTF invests in companies commercializing technologies being developed at UC San Diego (UCSD) or by UCSD alumni. Companies can originate in any school including, for example, Jacobs School of Engineering, Rady School of Management, Scripps Institute of Oceanography, or the Medical School. Technology areas of interest include analytics, social media, mobile, materials, medical devices, digital health, diagnostics, healthcare IT and advanced instrumentation. Of particular interest are technologies that can be matched with a targeted vertical market. For more information, interested parties may contact Triton at firstname.lastname@example.org
The Triton Fund
Rosibel Ochoa, 1-858-822-6775